- Home
- CRDF vs FATE Comparison
CRDF vs FATE Comparison
Compare CRDF & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- FATE
- Stock Information
- Founded
- CRDF 1999
- FATE 2007
- Country
- CRDF United States
- FATE United States
- Employees
- CRDF N/A
- FATE N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRDF Health Care
- FATE Health Care
- Exchange
- CRDF Nasdaq
- FATE Nasdaq
- Market Cap
- CRDF 144.4M
- FATE 116.5M
- IPO Year
- CRDF N/A
- FATE 2013
- Fundamental
- Price
- CRDF $2.05
- FATE $0.96
- Analyst Decision
- CRDF Strong Buy
- FATE Hold
- Analyst Count
- CRDF 5
- FATE 6
- Target Price
- CRDF $11.10
- FATE $3.30
- AVG Volume (30 Days)
- CRDF 1.1M
- FATE 1.4M
- Earning Date
- CRDF 11-06-2025
- FATE 11-11-2025
- Dividend Yield
- CRDF N/A
- FATE N/A
- EPS Growth
- CRDF N/A
- FATE N/A
- EPS
- CRDF N/A
- FATE N/A
- Revenue
- CRDF $545,000.00
- FATE $8,470,000.00
- Revenue This Year
- CRDF N/A
- FATE N/A
- Revenue Next Year
- CRDF N/A
- FATE N/A
- P/E Ratio
- CRDF N/A
- FATE N/A
- Revenue Growth
- CRDF N/A
- FATE N/A
- 52 Week Low
- CRDF $1.90
- FATE $0.66
- 52 Week High
- CRDF $5.64
- FATE $4.20
- Technical
- Relative Strength Index (RSI)
- CRDF 36.50
- FATE 40.81
- Support Level
- CRDF $2.03
- FATE $0.93
- Resistance Level
- CRDF $2.27
- FATE $1.08
- Average True Range (ATR)
- CRDF 0.12
- FATE 0.07
- MACD
- CRDF 0.04
- FATE -0.01
- Stochastic Oscillator
- CRDF 31.91
- FATE 13.79
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.